Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant SARS-CoV-2 Virus-like Particles (SARS2 VLPs)-S/M/E are produced in Insect SF21 cell expression system, assembled with Spike protein (S), Membrane protein (M) and Envelope protein (E). VLP is mimicking the native 3D structure of viruses which can elicit strong immune responses. However, VLPs lack viral genomic material which makes them non-infectious, unable to replicate and enhance the safety during manufacture and administration. SARS-CoV-2 VLPs can be used in the development of SARS-CoV-2 diagnostics and in vaccine development and R&D (including use as an immunogen).
Product Specifications
Structural Proteins
Spike protein (S), Membrane protein (M) and Envelope protein (E)
Expression Systems
Insect cell (Sf21) expression system
Buffer
20mM Tris-Cl, pH7.9, 100mM NaCl and 0.5mM EDTA
Form
Liquid
Alternative Names
SARS-Related Coronavirus 2 M/S/E Virus-like Particles; SARS-COV 2 M/S/E VLPs; SARS-Related Coronavirus 2 Virus-like Particles; SARS-COV 2 VLPs; VLPs; Virus-like Particles; SARS-Related Coronavirus 2 M/S/E; SARS-COV 2 M/S/E; COVID-19; SARS-Related Coronavirus 2 Membrane protein (M), Spike protein (S) and Envelope protein (E); SARS-COV 2 Membrane protein (M), Spike protein (S) and Envelope protein (E); SARS-CoV-2; COVID-19
Storage
Store at 4°C short term (2-4 weeks). Store at -80 °C long term. Avoid repeated freeze/thaw cycles.
Virus Background
Virus Family
Coronaviridae
Virus Species
SARS-CoV-2
Virus Overview
SARS-CoV-2 is a positive-sense single-stranded RNA virus (and hence Baltimore class IV) that is contagious in humans. As described by the US National Institutes of Health, it is the successor to SARS-CoV-1, the virus that caused the 2002-2004 SARS outbreak.Taxonomically, SARS-CoV-2 is a virus of the species severe acute respiratory syndrome-related coronavirus (SARSr-CoV). It is believed to have zoonotic origins and has close genetic similarity to bat coronaviruses, suggesting it emerged from a bat-borne virus. Research is ongoing as of February 2020 as to whether SARS-CoV-2 came directly from bats or indirectly through any intermediate hosts. The virus primarily spreads between people through close contact and via respiratory droplets produced from coughs or sneezes. It mainly enters human cells by binding to the angiotensin converting enzyme 2 (ACE2).